It was also observed that the combined administration of IL-17A monoclonal antibodies and anti-PD-L1 monoclonal antibodies significantly increased therapeutic efficacy by reducing PD-L1 expression in NSCLC tumor tissue (119). This evidence concerns the gene IL17A and non-small cell lung carcinoma.